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Introduction
Hu and colleagues [1] have risen to the challenge of 
seeking to identify a prognostic and predictive marker of 
sensitivity to radiotherapy in breast cancer. Radiotherapy 
for patients with breast cancer improves local disease 
control, and relapse free and overall survival [2]. Like 
most therapies, this comes at the cost of some morbidity 
[2,3], which is the driver for technical reﬁ  nements  in 
radiotherapy, including hypofractionation, partial breast 
radiation and intraoperative radiotherapy, with increas-
ing use and development of radiotherapy predicted for 
the future [4]. Th   ere are signiﬁ  cant beneﬁ  ts in targeting 
systemic breast cancer treatment, using, for example, 
oestrogen receptor (ER), or HER2 receptor expression. 
Trans criptome  proﬁ   ling may be used not only to 
categorise breast cancers, but in practice and randomised 
controlled trials to guide therapy [5]. In contrast, few 
inroads have been made into identifying prognostic or 
predictive biomarkers for radiotherapy in breast (or 
indeed any other) cancer [6].
Hu and colleagues [1] have made a bold attempt to 
address both biomarker questions in a single study. In 
130 patient samples and 4 breast cell lines, they examined 
Holliday junction recognition protein (HJURP), required 
for centromere protein A (CENPA) localisation [7-9] and 
involved in repairing double-strand DNA breaks [10]. By 
protein (western blot) and mRNA level (which at least in 
cell lines correlated), HJURP expression was higher in 
cancers than normal tissues and was associated with 
poor prognostic features, including ER-negative, high 
grade and high Ki67 proliferation index cancers. 
Remarkably, HJURP, divided empirically into high, mid 
and low tertiles, was an independent prognostic variable 
for disease free and overall survival in 130 women with 
breast cancer and outperformed many conventional 
prog  nostic features. Th  e prognostic hypothesis was 
tested and replicated on transcriptome data from ﬁ  ve 
further publicly available data sets, conﬁ  rming the asso-
ciation between high HJURP mRNA and prognosis. 
However, an independent association with radiotherapy 
outcomes as opposed to overall systemic outcomes 
(disease-free survival and overall survival) requires 
elucidation. Furthermore, questions regarding diﬀ  ering 
radio  therapy regimens, breast conservation or mastec-
tomy, extent of radiotherapy and diﬀ  erences in systemic 
therapy may all have a bearing on outcomes but were 
clearly beyond the remit of this study [1].
Th  e allied mechanistic questions examined in vitro
showed two breast cancer cell lines with high HJURP 
were more sensitive to radiation (via apoptosis) than two 
immortal lines with low levels of HJURP; HJURP levels 
were associated with CENPA, and HJURP knockdown 
reduced sensitivity to radiation. Subgroup analyses noted 
patients with high tumour HJURP given radiotherapy 
had a better disease-free survival than those who did not 
receive radiotherapy, suggesting the cell line studies were 
clinically relevant. Is HJURP the driving force for 
radiation sensitivity, or does it reﬂ  ect another aspect of 
tumour pathobiology? If radiation sensitivity is related to 
the role of HJURP in DNA damage repair, cells with 
higher HJURP should show enhanced repair and, 
therefore, radiation resistance, contrary to the data 
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are cell cycle regulated to achieve their functions in 
chromosome segregation [8,9] and proliferating cells are 
generally radiosensitive compared to non-proliferating 
cells. HJURP may simply reﬂ  ect proliferation, evidenced 
by the reduced proliferation in the HJURP knockdown 
cells, which become radioresistant. However, that HJURP 
is associated with radiation response suggests levels of 
HJURP are ineﬀ  ective for repair, and the cells lack other 
repair pathways. Increased HJURP may therefore result 
from failed attempts to repair ongoing damage. Alter-
natively, increased HJURP may indicate a block in cell 
cycle at a stage that is susceptible to radiotherapy, leading 
to hyper-activation of HJURP (and CENPA). Indeed, 
proliferation itself (measured by Ki67) is not a strong pre-
treatment indicator of response, whereas mitosis shows a 
signiﬁ  cant association with chemo/radiotherapy outcome 
[11]. Th   us, HJURP may act as a predictive marker because 
of its dual roles in accurate chromosome segregation 
during mitosis and in DNA repair and may represent the 
ﬁ  rst example of this class of predictive biomarkers.
Regardless of the mechanism(s) involved, the prog-
nostic potential will require testing in large randomised 
clinical trials of radiotherapy [3,12]. However, in most 
clinical and trials settings, formalin ﬁ  xed  paraﬃ   n 
embedded tissues may be the sole tissue resource 
available and while mRNA analyses are possible on such 
material, immunohistochemistry delineating the cell 
distribution of HJURP protein (cancer cell or stroma, 
tumour periphery, heterogeneous or homogeneous 
distri  bution) may be helpful. In trials, patient variables 
are balanced and should provide the potential to address 
the issue of sensitivity to radiation. A role for HJURP in 
normal (breast) tissues may also predict which patients 
might show increased sensitivity to radiotherapy and so 
indicate patients who would get excessive early or late 
radiotherapy eﬀ  ects [13].
While the data presented here [1] are inevitably 
preliminary, the ability to predict tumour sensitivity to 
radiotherapy in a way analogous to ER or HER2 is an 
intriguing prospect.
Conclusion
In HJURP, do we at last have a predictive and prognostic 
marker for who should (or should not) have radiotherapy? 
It is too soon to be sure, but HJURP clearly merits 
evaluation and requires validation as a prognostic and 
predictive marker in the multimodality treatment of 
breast cancer.
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